HN
Hansa Biopharma AB
HNSBF · OTC
$3.70 +0.00% (+$0.00)
Market Cap 3.63B kr
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.19x
P/FCF N/A
P/B N/A
Growth
79 /100
Growing Rev. growth 12.88%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak FCF margin 288.18%
Op. margin 310.69%
Gross margin 57.34%
Quality
3 /100
Poor ROA 71.74%
Asset turnover 0.18x
ROIC 71.73%
Debt
23 /100
High Int. coverage -3.06x
Current ratio 1.25x
Net debt/EBITDA N/A
Stability
39 /100
Moderate Profitable years 0
EPS volatility 32.73%
Beta 1.58x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na HNSBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Renée Julie Elisabet Aguiar-Lucander
Employees
125
Headquarters
Lund
Nadcházející události
05 LIS
Earnings
Upcoming earnings report